Notas sobre algúns nomes de pobos no Veneranda dies

O artigo trata sobre algúns nomes de pobos que aparecen no Veneranda dies, propoñendo algunhas identificacións dos nomes “Dacios” e “Romanos” que ata agora non se tomaran en consideración

Bendamustine in combination with gemcitabine and vinorelbine is an effective regimen as induction chemotherapy before autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma: Final results of a multicenter phase II study

Purpose: This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) as induction therapy before autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (HL). Patients and Methods: Patients with HL who were refractory to or had relapsed after one previous chemotherapy line were eligible. The primary end point was complete response (CR) rate after four cycles of therapy. Secondary end points were: overall response rate, stem-cell mobilization activity, and toxicity. Progression-free and overall survival were also evaluated. Results: In total, 59 patients were enrolled. After four cycles of therapy, 43 patients (73%) achieved CR, and six (10%) achieved partial response, for an overall response rate of 83%. The most common grade 3 to 4 nonhematologic toxicities included febrile neutropenia (n = 7) and infection (n = 4). Regarding hematologic toxicities, grade 3 to 4 thrombocytopenia and neutropenia were each experienced by eight patients (13.5%). CD34+ cells were successfully harvested in 55 of 57 evaluable patients, and 43 of 49 responding patients underwent ASCT. With a median follow-up of 29 months, the 2-year progression-free and overall survival rates for the total population were 62.2% and 77.6%, respectively. The same figures for patients undergoing autograft were 80.8% and 89.3%, respectively. Conclusion: This phase II study demonstrates that BeGEV is an effective salvage regimen able to induce CR in a high proportion of patients with relapsed or refractory HL before ASCT. These data provide a strong rationale for further development of the BeGEV regimen

Notes on some of the ethnonyms in the Veneranda dies

The article deals with some of the ethnonyms mentioned in the Veneranda dies, proposing some identifications for the names “Daci” and “Romani” that have not hitherto been considered

Notas sobre algunos nombres de pueblos en el Veneranda dies

El artículo trata sobre algunos nombres de pueblos que aparecen en el Veneranda dies y propone identificaciones para los “Dacios” y “Romanos” que hasta ahora no se habían tenido en consideración

Notas sobre algúns nomes de pobos no "Veneranda dies"

O artigo trata sobre algúns nomes de pobos que aparecen no Veneranda dies, propoñendo algunhas identificacións dos nomes “Dacios” e “Romanos” que ata agora non se tomaran en consideración